Andrographis: What Australians Should Know About Uses and Evidence

Why andrographis matters

Andrographis (Andrographis paniculata) is a medicinal herb long used in traditional systems of medicine across South and Southeast Asia. Interest in the plant has grown among consumers and researchers because of its reported immune-modulating and anti-inflammatory properties. For Australians seeking complementary approaches to common respiratory infections and immune support, understanding the evidence, uses and safety of andrographis is increasingly relevant.

Research and clinical evidence

Laboratory studies identify andrographolide and related compounds as the herb’s principal active constituents. These compounds have demonstrated anti‑inflammatory and antiviral activity in preclinical models, which has prompted clinical research. Several randomised controlled trials have examined andrographis preparations for acute upper respiratory tract infections and common colds; some trials report modest reductions in symptom severity and duration compared with placebo.

Systematic reviews and evidence summaries note potential benefits but highlight limitations: many trials are small, vary in dosage and formulation, and differ in quality. Research into andrographis for more serious viral illnesses has been preliminary; evidence is not sufficient to support routine clinical use for those conditions. Overall, andrographis shows promise for certain mild respiratory conditions, but higher‑quality, larger studies are needed to confirm effectiveness and optimal dosing.

Safety, interactions and practical use

Andrographis is generally reported as well tolerated in trial settings, with gastrointestinal upset and allergic reactions among the more commonly noted adverse effects. There are cautions regarding use in pregnancy and breastfeeding, and potential interactions with medications that affect immune function or blood clotting. As with any herbal product, quality and standardisation of preparations vary between manufacturers.

Consumers are advised to consult a healthcare professional—particularly if pregnant, breastfeeding, taking prescription medicines or managing chronic health conditions—before starting andrographis.

Conclusion and outlook

Andrographis remains of interest for its traditional use and emerging clinical data, especially for mild respiratory infections. While evidence suggests possible modest benefits, uncertainties about optimal dosing and long‑term safety remain. Australians considering andrographis should prioritise reputable products and professional advice. Continued well‑designed clinical trials will be important to clarify the herb’s role in integrative care and public health.